A selective cytopheretic inhibitory device for use during cardiopulmonary bypass surgery

Abstract

These results suggest that SCD-C therapy may disrupt the systemic leukocyte response during CPB, leading to improved outcomes for CPB-mediated MOD.

An Immunomodulatory Device Improves Insulin Resistance in Obese Porcine Model of Metabolic Syndrome

“…In preclinical models, SCD therapy has shown efficacy in acute multiorgan injury in severe sepsis. SCD therapy also prevents the inflammatory response to prolonged cardiopulmonary bypass, intracerebral hemorrhage (ICH), and ischemia/reperfusion injury (IRI) and improves myocardial contractility in CHF [45–48]. This device has been tested in 4 clinical studies in ICU patients with acute kidney injury and multiorgan dysfunction requiring dialysis with positive clinical outcomes and no device-related serious adverse events [49–52].…”

Effect of Air Exposure and Suction on Blood Cell Activation and Hemolysis in an In Vitro Cardiotomy Suction Model

“…It is possible that heparin alone can activate an inflammatory pathway or the chelation of calcium ion by citrate may decrease activation. 11 …”

Experience With Pediatric Medical Device Development

“…It follows that the preferential sequestration of inflammatory CD14 hi monocytes is enhanced in the low iCa environment. The selectivity of binding of the highest activated leukocytes has been repeatedly observed in preclinical animal models where systemic CD11R3: the porcine analog of human CD11b (21), levels decrease through the treatment course (10,11,22,23). This effect was measured directly in a clinical trial by comparing the CD11R3 relative fluorescence of the circulating cells in the peripheral blood to those directly associated with the SCD (24).…”

“…This effect was measured directly in a clinical trial by comparing the CD11R3 relative fluorescence of the circulating cells in the peripheral blood to those directly associated with the SCD (24). These results when taken together (10,11,(22)(23)(24)(25), suggest a SCD mechanism of action with a simultaneous, combination effect to transiently sequester activated circulating neutrophils and monocytes, with enhanced selectivity for inflammatory leukocytes, which alters the overall activation of bound and processed leukocytes. Clinical efficacy in AKI with Multi-Organ Dysfunction (MOD) may be due to sequestration and immunomodulation of leukocytes in the SCD.…”